Differential diagnosis and progress monitoring in Progressive Supranuclear Palsy – a potential role of pulmonary function tests
Objective: To determine the utility of pulmonary function tests in the differential diagnosis and monitoring of disease progression of Progressive Supranuclear Palsy. Background: Pulmonary complications…Results of a Phase 1, Single Ascending Dose, Placebo-Controlled Study of ABBV-8E12 in Patients with Progressive Supranuclear Palsy and Phase 2 Study Design
Objective: To present the results of a phase 1 study of ABBV-8E12 in subjects with Progressive Supranuclear Palsy (PSP) and design of a phase 2…Primary progressive apraxia: an unusual ideomotor syndrome
Objective: We describe and demonstrate by video 2 cases of primary ideomotor progressive apraxia with progressive difficulty with hand dexterity and manipulation and mild parkinsonism…Phenotypic Heterogeneity in PSP Variants – A Case Series
Objective: To present the phenotypic heterogeneity we observed in 5 PSP variants. Background: Progressive supranuclear palsy (PSP) is a primary tauopathy characterised by progressive gait…Progressive supranuclear palsy presenting with corticobasal syndrome: a case report
Objective: Clinical description and interpretation of complementary diagnostic exams of a patient with probable PSP with corticobasal syndrome phenotype (PSP-CBS). Background: Underlying pathologies of CBS…Pre-synaptic dopaminergic deficit in a patient with familial FTD
Objective: Clinical description of a patient with familial FTD with a rapidly progressive parkinsonism. Background: FTD typically presents with behavioral and cognitive deficits, but extrapyramidal…Atypical and slowly progressive FTDP-17 caused by MAPT p.R406W mutations – similarities to AD and PSP.
Objective: We compiled clinical data of a new kindred with the MAPT c.1216C>T (p.Arg406Trp; R406W) mutation and systematically reviewed previously described cases with this mutation.…PBB3 Imaging in Parkinsonian disorders: evidence for binding to abnormally aggregated proteins in addition to tau proteins
Objective: To study selective regional binding for tau pathology in vivo, using PET with [11C]PBB3 ([11C]methylamino pyridin-3-yl buta-1,3-dienyl benzo[d]thiazol-6-ol) in tauopathies, and in conditions not…IGF-1 levels are associated with CSF pathology and executive dysfunction in de novo Parkinson’s disease patients
Objective: To investigate whether serum insulin-like growth factor-1 (IGF-1) is associated with clinical-neuropsychiatric, imaging and CSF markers of PD pathology in patients with early, drug-naïve…Diabetes Mellitus and Parkinson’s Disease
Objective: To investigate the association of type 2 diabetes mellitus (DM) with markers of Parkinson’s pathology in patients with early de novo Parkinson’s disease (PD).…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- 14
- Next Page »